The Fever and Antipyretic in Critically Illness Evaluation Study (FACE)

• 28 days mortality [ Time Frame: 28days after ICU admission ] [ Designated as safety issue: No ]
  

• ICU free days at 28 days [ Time Frame: 28 days after ICU admission ] [ Designated as safety issue: No ]
  
• Hospital free days at 28 days [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  
• Ventilator free days at 28 days [ Time Frame: 28 days at ICU admission ] [ Designated as safety issue: No ]
  
• Renal replacement therapy free days at 28 days [ Time Frame: 28 days at ICU admission ] [ Designated as safety issue: No ]
  

Fever is common in critically ill patients.Antipyretic therapy for fever is routinely performed in intensive care.There are studies to assess the relationship between fever and mortality in non-neurological ICU. However, all of them did not have any information of antipyretic therapy. There are two small, single center RCT, which suggested a potential risk for antipyretic therapy. Thus, a large RCT might be ethically difficult.

It is unfortunate that there is not enough information on how the investigators should control body temperature in non-neurological critically ill patients, because fever is a very common physiological abnormality in this cohort. From the beginning, it would, therefore, be desirable to understand several aspects of fever and antipyretic therapy in ICU patients, as 1)How often fever occurs in our ICUs, 2)To what degree fever is independently associated with mortality?, 3)How often antipyretic therapy is prescribed?, 4)How effectively antipyretic can decrease temperature?, 5)How different is lowering temperature with medications compared with cooling?, 6)To what degree antipyretic is independently associated with mortality?

Thus, the investigators plan to address these questions by conducting a multi-national multi-center prospective observational trial, named "The Fever and Antipyretic in Critically illness evaluation study" (The FACE study)